Triptans and CGRP blockade – impact on the cranial vasculature

CGRP and its receptors

(2017) Debbie L. Hay et al.   HEADACHE

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Pathophysiology of Migraine: A Disorder of Sensory Processing

(2017) Peter J. Goadsby et al.   PHYSIOLOGICAL REVIEWS

A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan

(2016) K Ibrahimi et al.   CEPHALALGIA

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

New strategies for the treatment and prevention of primary headache disorders

(2016) Nathaniel M. Schuster et al.   Nature Reviews Neurology

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment

(2015) Lars Edvinsson   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38

(2014) Faisal Mohammad Amin et al.   BRAIN

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

(2014) David W Dodick et al.   LANCET NEUROLOGY

Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience

(2013) Messoud Ashina et al.   CEPHALALGIA

The effect of sumatriptan on cephalic arteries: A 3T MR-angiography study in healthy volunteers

(2013) Faisal Mohammad Amin et al.   CEPHALALGIA

Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study

(2013) Faisal Mohammad Amin et al.   LANCET NEUROLOGY

Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine

(2012) Eric L Moore et al.   BRITISH JOURNAL OF PHARMACOLOGY

Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers

(2011) Faisal Mohammad Amin et al.   CEPHALALGIA

Evidence for a vascular factor in migraine

(2010) Mohammad S. Asghar et al.   ANNALS OF NEUROLOGY

Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries

(2010) Lars Edvinsson et al.   CEPHALALGIA

Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial

(2010) Michel D Ferrari et al.   CEPHALALGIA

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

(2010) Jakob Møller Hansen et al.   CEPHALALGIA

Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers

(2010) M. S. Asghar et al.   NEUROLOGY

Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects

(2010) Kayi Y. Chan et al.   PHARMACOLOGY & THERAPEUTICS

Nitroglycerin provocation in normal subjects is not a useful human migraine model?

(2009) JF Tvedskov et al.   CEPHALALGIA

Origin of pain in migraine: evidence for peripheral sensitisation

(2009) Jes Olesen et al.   LANCET NEUROLOGY

The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs

(2009) Carlos M. Villalón et al.   PHARMACOLOGY & THERAPEUTICS

Migraine: where and how does the pain originate?

(2009) Karl Messlinger   EXPERIMENTAL BRAIN RESEARCH

PACAP38 induces migraine-like attacks in patients with migraine without aura

(2008) Henrik Winther Schytz et al.   BRAIN

The vascular theory of migraine—a great story wrecked by the facts

(2008) Peter J. Goadsby   BRAIN

CGRP blockers in migraine therapy: where do they act?

(2008) L Edvinsson   BRITISH JOURNAL OF PHARMACOLOGY

CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat

(2008) J Zeller et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Discovery and Development of the Triptans, a Major Therapeutic Breakthrough

(2008) Patrick P.A. Humphrey   HEADACHE

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

(2008) Tony W Ho et al.   LANCET

Inhibitory effect of BIBN4096BS, CGRP8-37, a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery

(2007) L Edvinsson et al.   BRITISH JOURNAL OF PHARMACOLOGY